Clinical trials: Moderate Plaque Psoriasis
Plaque Psoriasis
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.
- Trial name
- NCT07326813
- Testing
- D-2570 Tablet, BMS-986165 Tablet
- Where
- China
- Volunteers
- 477 people
- Sponsor
- InventisBio Co., Ltd
Psoriasis Vulgaris
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months…
- Trial name
- NCT02125279
- Testing
- Calcitriol
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 54 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis
The aim of this proof of concept study is to show the safety and efficacy of 0.5 % dermal roflumilast cream in the treatment of plaque psoriasis in adults.
- Trial name
- NCT00746434
- Testing
- Roflumilast cream
- Sponsor
- AstraZeneca
Plaque Psoriasis
A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
This randomized, double-blinded dose-finding study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis.
- Trial name
- AFFIRM-35 (NCT03591887)
- Testing
- ABY-035
- Where
- 18 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Affibody
Psoriasis
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic…
- Trial name
- RESPONSE (NCT00096928)
- Where
- 182 sites in United States
- Volunteers
- 1,846 people
- Sponsor
- Genentech, Inc.
Moderate-to-severe Plaque Psoriasis
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.
- Trial name
- SPARROW (NCT06142357)
- Testing
- Secukinumab
- Where
- 16 sites in Russia
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
- Trial name
- NCT03179605
- Testing
- DFD06
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis
Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis.
- Trial name
- NCT00147329
- Testing
- MM-093
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merrimack Pharmaceuticals
Moderate to Severe Chronic Plaque Psoriasis
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a phase II, randomised, double-blind, placebo-controlled, multiple-dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02223039
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Plaque Psoriasis
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis
The purpose of this study is to establish proof of efficacy for namilumab in moderate to severe plaque psoriasis, measured as Psoriasis Area and Severity Index (PASI)75 response rate at Week 12.
- Trial name
- NCT02129777
- Testing
- Namilumab
- Where
- 10 sites in Canada
- Volunteers
- 122 people
- Sponsor
- Takeda
Moderate to Severe Plaque Psoriasis
Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.
- Trial name
- NCT02607774
- Testing
- Midazolam, AIN457
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis
This study seeks to show whether there is a benefit of prescribing Enstilar with Otezla in the treatment of patients with moderate plaque type psoriasis.
- Trial name
- NCT03441789
- Testing
- Enstilar, Vehicle, Otezla
- Where
- 4 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- L.H. Kircik, M.D.
Plaque Psoriasis
LAS41008 in Moderate to Severe Chronic Plaque Psoriasis
The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis
- Trial name
- NCT01726933
- Testing
- LAS41008, LASW1835
- Where
- 4 sites in Austria, Germany and 2 more
- Volunteers
- 839 people
- Sponsor
- Almirall, S.A.
Moderate to Severe Plaque Psoriasis
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of…
- Trial name
- NCT07051538
- Testing
- SHR-1139 Injections
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to <18 years of age with moderate to severe…
- Trial name
- BE TOGETHER (NCT06425549)
- Testing
- bimekizumab, ustekinumab
- Where
- 42 sites in United States, Belgium and 8 more
- Volunteers
- 176 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis
The purpose of this study is to evaluate the efficacy of adding methotrexate to etanercept compared with etanercept monotherapy as measured by the percentage of participants achieving a 75% improvement from baseline in the…
- Trial name
- NCT01001208
- Testing
- Methotrexate, Etanercept
- Volunteers
- 478 people
- Sponsor
- Amgen
Plaque Psoriasis
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque…
- Trial name
- NCT05442788
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriasis
Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis
This study will evaluate whether pentoxifylline, when used as an add-on treatment to standard topical therapy, is effective and safe for adults with mild-to-moderate plaque psoriasis.
- Trial name
- PTX-PSO (NCT07626788)
- Testing
- Pentoxifylline 400 mg Oral Tablet
- Where
- Thailand
- Volunteers
- 140 people
- Sponsor
- Wasuchon Chaichan
Chronic Plaque Psoriasis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
- Trial name
- BE ABLE 2 (NCT03010527)
- Testing
- Bimekizumab
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 217 people
- Sponsor
- UCB Biopharma SRL